A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
Recruiting
Phase 2
Interventional Study
Colitis Ulcerative
Ulcerative Colitis
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 100 (estimated)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this protocol is to evaluate the efficacy of MK-8690 in participants with moderately to severely active ulcerative colitis. The primary hypothesis is that MK-8690 is superior to placebo with respect to the proportion of participants achieving clinical remission per Modified Mayo Score at Week 12.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
The main inclusion criteria include but are not limited to the following:
* Has had ulcerative colitis (UC) (from onset of symptoms) for at least 3 months before Randomization
* Has moderately to severely active UC
* Has a weight ≥40 kg
* Satisfies at least 1 of the criteria: Has had an inadequate …
Contacts